# FondaRed



COMPARING THE EFFICACY AND TOLERABILITY OF FONDAPARINUX WITH ENOXAPARIN FOR THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS

### Background

- Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) are the subsets of Venous Thromboembolism (VTE) and primary preventable cause of morbidity and mortality.
- For several years, the standard therapy of Low Molecular Weight Heparin (LMWH) has been in use.
- ► Fondaparinux is the first approved anticoagulant drug among factor 10a inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis.
- However, sparse data is available supporting the benefit-risk profile of fondaparinux v/s enoxaparin in a real-world group.

# Objective

The purpose of the study was to compare the effectiveness and tolerability of fondaparinux v/s enoxaparin in Indian patients with symptomatic deep vein thrombosis in a long-term real-world setting.



### **Study details**

A retrospective, longitudinal, real-world, observational study

Involved 1008 patients diagnosed with deep vein thrombosis

Fondaparinux group (n=503) Weight-based once-daily SC injection of -5 mg for body weight < 50 kg -7.5 mg for body weight between 50 and 100 kg -10 mg for body weight > 100 kg

Enoxaparin group (n=505) Twice-daily SC injection of 1 mg/kg of body weight

#### **Outcome measured**

**Efficacy outcomes:** Incidences of recurrent symptomatic thrombosis events (DVT or PE), duration of the event from the baseline, and the type of recurrence.


Safety outcomes: Major and minor bleeding events.

### **Results**

- The recurrent incidences of DVT were lower in the fondaparinux group compared to enoxaparin (Fig. 1A).
- No significant difference was observed between both the groups in -
  - Total episodes of clinically suspected recurrence of symptomatic VTE (p > 0.05).
  - Duration of a recurrent event (Fig. 1B).

### **Results**

#### **Recurrence Events (n) of DVT**



otady rimein

B

A




Figure 1: A) Number of deep vein thrombosis (DVT) recurrence events; B) Duration of event from baseline

- ▶ No fatal and non-fatal PE events were observed.
- Major and minor bleeding events were higher in the enoxaparin group than the fondaparinux group, though the difference was not statistically significant. (Fig. 2).
- The majority of the thromboembolism and major bleeding events occurred in the '50–100 kg' bodyweight category.

#### **Results**




Figure 2: Count of bleeding events is shown from baseline to the end of the study duration

## Conclusion

Fondaparinux showed non-inferior effectiveness and a comparable tolerability profile with enoxaparin for the management of symptomatic deep vein thrombosis.



# Take home points

9	Fondaparinux, a pentasaccharide, is the first of a new class of synthetic antithrombotic drugs that acts through specific inhibitionof factor Xa.
2	Significantly lower incidence of VTE and DVT was observed with fondaparinux compared to enoxaparin in other studies.
3	Between the two drugs, there was a significant relationship between the onset of symptoms and the initiation of DVT therapy.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory.

#### **Reference:**

Ramakrishna P, Gupta PC, Pai P, Rai K, Rajkumar M, Sahu T, et al. Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study. Drugs Real World Outcomes. 2021 Aug 25.